{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:16:43Z","timestamp":1789827403858,"version":"4.0.1"},"reference-count":156,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"unspecified","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,7,17]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This systematic literature review (SLR) aims to update the evidence regarding therapeutic strategies in difficult-to-treat rheumatoid arthritis (D2T RA), building on the previous SLR informing the European Alliance of Associations for Rheumatology (EULAR) points to consider for the management of D2T RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Three research questions addressed efficacy or safety of treatments in patients with RA with (1) active disease and limited treatment options; (2) active disease with \u22652 prior biologic\/targeted synthetic disease-modifying antirheumatic drugs (b\/tsDMARDs) and (3) poor health-related quality of life and low objective disease activity (non-pharmacological interventions). MEDLINE, Embase and Cochrane Library were searched until July 2025. Meta-analysis and meta-regression were conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We screened 8589 records and included 131 studies. For research question (RQ)1, evidence on DMARD efficacy and safety was synthesised across a wide spectrum of comorbidities including obesity, cardiovascular disease, history of malignancy and respiratory comorbidities. For RQ2, all b\/tsDMARDs except otilimab demonstrated better efficacy than placebo (mostly high risk of bias). Meta-regression showed efficacy was maintained for Janus kinase inhibitors (JAKi) despite increasing number of prior bDMARD failures (1 to \u22653). Safety results confirmed the increased occurrence of infection and malignancy with JAKi. For RQ3, limited evidence suggested orthopaedic surgical intervention as a potential non-pharmacological option in patients with D2T RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This SLR summarised evidence supporting DMARD efficacy\/safety across multiple comorbidities. In patients with active RA with \u22652 prior bDMARDs, JAKi offer substantial clinical benefits but require careful risk stratification given cardiovascular and malignancy risks. Furthermore, standardised reporting and dedicated studies on non-pharmacological interventions are urgently needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42024593584.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2026-006860","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:10:20Z","timestamp":1785845420000},"page":"e006860","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic approaches for difficult-to-treat rheumatoid arthritis: a systematic literature review of current evidence"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4213-2533","authenticated-orcid":false,"given":"Golnaz","family":"Shams","sequence":"first","affiliation":[{"name":"Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s Mikl\u00f3s","family":"Dorg\u00f3","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ripepi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1889-8006","authenticated-orcid":false,"given":"Emma","family":"Wettersand","sequence":"additional","affiliation":[{"name":"Rheumatology, Theme Inflammation and Ageing, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Rheumatology division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Malczuk","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases and Rheumatology, Military Institute of Medicine\u2014National Research Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Neumeister","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sla\u0111ana","family":"Rumpl Tunji\u0107","sequence":"additional","affiliation":[{"name":"Association Remisija, EULAR PARE Patient Research Partner, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Wildner","sequence":"additional","affiliation":[{"name":"University Library, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-491X","authenticated-orcid":false,"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Ludwig Maximilians University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-3228","authenticated-orcid":false,"given":"Gy\u00f6rgy","family":"Nagy","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Semmelweis University, Budapest, Hungary"},{"name":"Heart and Vascular Center, Semmelweis University, Budapest, Hungary"},{"name":"Semmelweis University, Department of Genetics, Cell- and Immunobiology, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1432-3671","authenticated-orcid":false,"given":"Jo\u00e3o Eurico","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Medical School, University of Lisbon and ULS Santa Maria; Lisbon Academic Medical Center, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M","family":"van Laar","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paco M J","family":"Welsing","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8895-6941","authenticated-orcid":false,"given":"Paul","family":"Studenic","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"2026080405101039000_12.3.e006860.1","first-page":"591","article-title":"Global epidemiology of rheumatoid arthritis","volume":"18","author":"Finckh","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2026080405101039000_12.3.e006860.2","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2026080405101039000_12.3.e006860.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216694"},{"key":"2026080405101039000_12.3.e006860.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.123919"},{"key":"2026080405101039000_12.3.e006860.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2026080405101039000_12.3.e006860.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217344"},{"key":"2026080405101039000_12.3.e006860.7","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/art.42767","article-title":"Poly-refractory rheumatoid arthritis: An uncommon subset of difficult-to-treat disease with distinct inflammatory and noninflammatory phenotypes","volume":"76","author":"David","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026080405101039000_12.3.e006860.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-00541-7"},{"key":"2026080405101039000_12.3.e006860.9","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001512","article-title":"Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis","volume":"7","author":"Roodenrijs","year":"2021","journal-title":"RMD Open"},{"key":"2026080405101039000_12.3.e006860.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220973"},{"key":"2026080405101039000_12.3.e006860.11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac584"},{"key":"2026080405101039000_12.3.e006860.12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ard.2025.10.007","article-title":"Difficult-to-treat rheumatoid arthritis: systematic review and meta-analysis on global prevalence","volume":"85","author":"Xie","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"2026080405101039000_12.3.e006860.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae544"},{"key":"2026080405101039000_12.3.e006860.14","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/S2665-9913(24)00340-0","article-title":"The concept of difficult-to-treat disease in rheumatology: where next?","volume":"7","author":"Nagy","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"2026080405101039000_12.3.e006860.15","doi-asserted-by":"crossref","unstructured":"Page MJ , McKenzie JE , Bossuyt PM , et al . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372. doi:10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"2026080405101039000_12.3.e006860.16","doi-asserted-by":"crossref","unstructured":"Higgins J , Thomas J , Chandler J , eds. Cochrane handbook for systematic reviews of interventions.2nd edn. Chichester, UK: John Wiley & Sons, 2019.","DOI":"10.1002\/9781119536604"},{"key":"2026080405101039000_12.3.e006860.17","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2026080405101039000_12.3.e006860.18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026080405101039000_12.3.e006860.19","unstructured":"Wells GA , Shea B , O\u2019Connell D , et al . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000."},{"key":"2026080405101039000_12.3.e006860.20","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117"},{"key":"2026080405101039000_12.3.e006860.21","doi-asserted-by":"crossref","unstructured":"Viechtbauer W . Conducting meta-analyses in R with the metafor package. J Stat Softw 2010. doi:10.18637\/jss.v036.i03","DOI":"10.18637\/jss.v036.i03"},{"key":"2026080405101039000_12.3.e006860.22","first-page":"1657","article-title":"The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age","volume":"40","author":"Specker","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2026080405101039000_12.3.e006860.23","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00296-024-05651-z","article-title":"Managing rheumatoid arthritis and cardiovascular disease: the role of physical medicine and rehabilitation","volume":"44","author":"Sagtaganov","year":"2024","journal-title":"Rheumatol Int"},{"key":"2026080405101039000_12.3.e006860.24","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003912","article-title":"Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b\/4 randomised safety study","volume":"10","author":"Buch","year":"2024","journal-title":"RMD Open"},{"key":"2026080405101039000_12.3.e006860.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222543"},{"key":"2026080405101039000_12.3.e006860.26","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/joim.20064","article-title":"Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: a nationwide cohort study","volume":"297","author":"Cho","year":"2025","journal-title":"J Intern Med"},{"key":"2026080405101039000_12.3.e006860.27","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-023-03249-7","article-title":"The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study","volume":"26","author":"Di Muzio","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"2026080405101039000_12.3.e006860.28","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13075-020-02229-5","article-title":"Interleukin-6 receptor blockade or TNF\u03b1 inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials","volume":"22","author":"Genovese","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2026080405101039000_12.3.e006860.29","doi-asserted-by":"crossref","DOI":"10.1093\/rap\/rkaa027","article-title":"Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus","volume":"4","author":"Chen","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"2026080405101039000_12.3.e006860.30","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1093\/rheumatology\/keaa810","article-title":"Influence of inflammatory and non-inflammatory rheumatic disorders on the clinical and biological profile of type-2 diabetes","volume":"60","author":"Avouac","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026080405101039000_12.3.e006860.31","doi-asserted-by":"publisher","DOI":"10.1002\/art.22070"},{"key":"2026080405101039000_12.3.e006860.32","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225014"},{"key":"2026080405101039000_12.3.e006860.33","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1002\/acr.24867","article-title":"Obesity and response to advanced therapies in rheumatoid arthritis","volume":"74","author":"Baker","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026080405101039000_12.3.e006860.34","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190282"},{"key":"2026080405101039000_12.3.e006860.35","first-page":"1726","article-title":"Obesity and response to biological therapy in rheumatoid arthritis: the role of body mass index and adipose tissue cytokines","volume":"40","author":"Novella-Navarro","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2026080405101039000_12.3.e006860.36","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002103","article-title":"Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies","volume":"8","author":"Dikranian","year":"2022","journal-title":"RMD Open"},{"key":"2026080405101039000_12.3.e006860.37","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.55730\/1300-0144.5698","article-title":"Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKB\u0130O registry","volume":"53","author":"Karata\u015f","year":"2023","journal-title":"Turk J Med Sci"},{"key":"2026080405101039000_12.3.e006860.38","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s40744-023-00599-1","article-title":"Effect of filgotinib on body mass index (BMI) and effect of baseline BMI on the efficacy and safety of filgotinib in rheumatoid arthritis","volume":"10","author":"Balsa","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2026080405101039000_12.3.e006860.39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75673-7","article-title":"Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs","volume":"10","author":"Abuhelwa","year":"2020","journal-title":"Sci Rep"},{"key":"2026080405101039000_12.3.e006860.40","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez535"},{"key":"2026080405101039000_12.3.e006860.41","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/acr.21768","article-title":"Obesity and reduction of the response rate to anti-tumor necrosis factor \u03b1 in rheumatoid arthritis: an approach to a personalized medicine","volume":"65","author":"Gremese","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026080405101039000_12.3.e006860.42","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-074864","article-title":"Comparative effectiveness of biologics in patients with rheumatoid arthritis stratified by body mass index: a cohort study in a Swiss registry","volume":"14","author":"Vallejo-Yag\u00fce","year":"2024","journal-title":"BMJ Open"},{"key":"2026080405101039000_12.3.e006860.43","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/art.43034","article-title":"Metabolic syndrome, adipokines, and response to advanced therapies in rheumatoid arthritis","volume":"77","author":"Baker","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"2026080405101039000_12.3.e006860.44","doi-asserted-by":"crossref","DOI":"10.1186\/s13018-019-1492-3","article-title":"Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients","volume":"14","author":"Xie","year":"2019","journal-title":"J Orthop Surg Res"},{"key":"2026080405101039000_12.3.e006860.45","doi-asserted-by":"crossref","DOI":"10.1186\/s13018-021-02271-2","article-title":"Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies","volume":"16","author":"Mori","year":"2021","journal-title":"J Orthop Surg Res"},{"key":"2026080405101039000_12.3.e006860.46","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/14397595.2020.1812835","article-title":"Efficacy and safety of sodium risedronate for glucocorticoid-induced osteoporosis with rheumatoid arthritis (RISOTTO study): A multicentre, double-blind, randomized, placebo-controlled trial","volume":"31","author":"Fujieda","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2026080405101039000_12.3.e006860.47","doi-asserted-by":"crossref","DOI":"10.1111\/ijn.13199","article-title":"Effects of a self-determination theory-based physical activity programme for postmenopausal women with rheumatoid arthritis: a randomized controlled trial","volume":"29","author":"Yun","year":"2023","journal-title":"Int J Nurs Pract"},{"key":"2026080405101039000_12.3.e006860.48","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.afos.2021.08.001","article-title":"Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: an open-label, randomized, pilot study","volume":"7","author":"Mochizuki","year":"2021","journal-title":"Osteoporos Sarcopenia"},{"key":"2026080405101039000_12.3.e006860.49","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1080\/14397595.2020.1812793","article-title":"Three-year results of denosumab treatment for osteoporosis in women with rheumatoid arthritis and primary osteoporosis: a clinical observational study","volume":"31","author":"Mochizuki","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2026080405101039000_12.3.e006860.50","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225914"},{"key":"2026080405101039000_12.3.e006860.51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40801-022-00338-y","article-title":"Persistence and safety of golimumab in elderly patients with rheumatoid arthritis and renal dysfunction in a real-world setting","volume":"10","author":"Yokoyama","year":"2023","journal-title":"Drugs Real World Outcomes"},{"key":"2026080405101039000_12.3.e006860.52","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-024-01360-w","article-title":"Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study","volume":"24","author":"Nakayama","year":"2024","journal-title":"Clin Exp Med"},{"key":"2026080405101039000_12.3.e006860.53","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1111\/bcp.14641","article-title":"Risk of haematological events and preventive effect of folic acid in methotrexate users with chronic kidney disease and rheumatoid arthritis: analysis of the Japanese Adverse Drug Event Report database","volume":"87","author":"Mitsuboshi","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2026080405101039000_12.3.e006860.54","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00296-020-04547-y","article-title":"Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction","volume":"40","author":"Lee","year":"2020","journal-title":"Rheumatol Int"},{"key":"2026080405101039000_12.3.e006860.55","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1093\/rheumatology\/keaf050","article-title":"Efficacy and safety of first-line targeted synthetic DMARDs in rheumatoid arthritis patients with chronic kidney disease","volume":"64","author":"Yoshimura","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026080405101039000_12.3.e006860.56","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-024-00446-y","article-title":"Efficacy and safety of baricitinib in rheumatoid arthritis patients with moderate renal impairment: a multicenter propensity score matching study","volume":"8","author":"Maeyama","year":"2024","journal-title":"BMC Rheumatol"},{"key":"2026080405101039000_12.3.e006860.57","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.1669"},{"key":"2026080405101039000_12.3.e006860.58","doi-asserted-by":"crossref","unstructured":"Fukuda W , Hanyu T , Katayama M , et al . Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital. Arthritis Res Ther 2019;21. doi:10.1186\/s13075-019-2053-1","DOI":"10.1186\/s13075-019-2053-1"},{"key":"2026080405101039000_12.3.e006860.59","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001095","article-title":"Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis","volume":"6","author":"Harigai","year":"2020","journal-title":"RMD Open"},{"key":"2026080405101039000_12.3.e006860.60","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1874312902115010039","article-title":"Effect of low-dose corticosteroid use on HBV reactivation in HBsAg-positive rheumatoid arthritis patients","volume":"15","author":"Jeong","year":"2021","journal-title":"Open Rheumatol J"},{"key":"2026080405101039000_12.3.e006860.61","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/liv.15793","article-title":"HBV reactivation in HBsAg\u2212\/HBcAb+ rheumatoid arthritis patients receiving biologic\/targeted synthetic DMARDs","volume":"44","author":"Kuo","year":"2024","journal-title":"Liver International"},{"key":"2026080405101039000_12.3.e006860.62","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-59406-4","article-title":"Moderate risk of hepatitis B virus reactivation in HBsAg\u2212\/HBcAb+ carriers receiving rituximab for rheumatoid arthritis","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci Rep"},{"key":"2026080405101039000_12.3.e006860.63","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1007\/s10620-020-06725-1","article-title":"Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing tocilizumab-containing treatment","volume":"66","author":"Kuo","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2026080405101039000_12.3.e006860.64","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1097\/MEG.0000000000002015","article-title":"Direct antiviral drugs in the treatment of hepatitis C-infected rheumatoid arthritis Egyptian cohort: safety and clinical impact","volume":"33","author":"Lashen","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026080405101039000_12.3.e006860.65","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160983"},{"key":"2026080405101039000_12.3.e006860.66","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/1756-185X.13010","article-title":"Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation","volume":"20","author":"Chen","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"2026080405101039000_12.3.e006860.67","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/acr.22786","article-title":"Safety of abatacept in rheumatoid arthritis with serologic evidence of past or present hepatitis B virus infection","volume":"68","author":"Padovan","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026080405101039000_12.3.e006860.68","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X231186874","article-title":"Efficacy and safety of abatacept in patients with rheumatoid arthritis with previous malignancy","volume":"15","author":"Kunishita","year":"2023","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026080405101039000_12.3.e006860.69","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/art.42809","article-title":"Effect of recent antirheumatic drug on features of rheumatoid arthritis-associated lymphoproliferative disorders","volume":"76","author":"Hoshida","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026080405101039000_12.3.e006860.70","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s12282-024-01618-x","article-title":"Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors","volume":"31","author":"Ruiz","year":"2024","journal-title":"Breast Cancer"},{"key":"2026080405101039000_12.3.e006860.71","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1007\/s10067-020-05318-7","article-title":"Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy","volume":"39","author":"Pundole","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2026080405101039000_12.3.e006860.72","doi-asserted-by":"crossref","first-page":"152341","DOI":"10.1016\/j.semarthrit.2023.152341","article-title":"Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: results from the BIOBADASER register","volume":"64","author":"Molina-Collada","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2026080405101039000_12.3.e006860.73","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/S2665-9913(24)00379-5","article-title":"Survival in patients with rheumatoid arthritis and recently diagnosed early-stage colorectal, lung, or prostate cancer receiving tumour necrosis factor inhibitors: a retrospective cohort study","volume":"7","author":"Ruiz","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"2026080405101039000_12.3.e006860.74","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005247","article-title":"Cancer recurrence risk with bDMARD treatment in patients with rheumatoid arthritis and a history of cancer: a nationwide Danish register-based cohort study","volume":"11","author":"Westermann","year":"2025","journal-title":"RMD Open"},{"key":"2026080405101039000_12.3.e006860.75","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1093\/rheumatology\/kez676","article-title":"Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis","volume":"59","author":"Md Yusof","year":"2020","journal-title":"Rheumatology"},{"key":"2026080405101039000_12.3.e006860.76","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.semarthrit.2019.11.010","article-title":"Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: a cohort study","volume":"50","author":"Kang","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2026080405101039000_12.3.e006860.77","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214261"},{"key":"2026080405101039000_12.3.e006860.78","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.semarthrit.2019.03.007","article-title":"Comparative safety of abatacept in rheumatoid arthritis with COPD: a real-world population-based observational study","volume":"49","author":"Suissa","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2026080405101039000_12.3.e006860.79","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejim.2023.08.025","article-title":"Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis","volume":"119","author":"Atienza-Mateo","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2026080405101039000_12.3.e006860.80","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab317"},{"key":"2026080405101039000_12.3.e006860.81","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","article-title":"Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients","volume":"59","author":"Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2026080405101039000_12.3.e006860.82","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-024-00374-x","article-title":"Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study","volume":"8","author":"Tsujii","year":"2024","journal-title":"BMC Rheumatol"},{"key":"2026080405101039000_12.3.e006860.83","first-page":"4687","article-title":"Iguratimod attenuates general disease activity and improves lung function in rheumatoid arthritis-associated interstitial lung disease patients","volume":"25","author":"Shu","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2026080405101039000_12.3.e006860.84","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/1756-185X.14808","article-title":"The additional treatment value of immunoglobulin for the treatment of rheumatoid arthritis complicated with interstitial lung disease: a propensity score\u2010matched pilot study","volume":"26","author":"Shen","year":"2023","journal-title":"Int J of Rheum Dis"},{"key":"2026080405101039000_12.3.e006860.85","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10787-022-00936-w","article-title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease","volume":"30","author":"Tardella","year":"2022","journal-title":"Inflammopharmacol"},{"key":"2026080405101039000_12.3.e006860.86","doi-asserted-by":"crossref","unstructured":"Wang S , Li Y , Tang Y , et al . A prospective observational cohort study of the efficacy of tofacitinib plus iguratimod on rheumatoid arthritis with usual interstitial pneumonia. Front Immunol 2023;14. doi:10.3389\/fimmu.2023.1215450","DOI":"10.3389\/fimmu.2023.1215450"},{"key":"2026080405101039000_12.3.e006860.87","doi-asserted-by":"crossref","first-page":"152517","DOI":"10.1016\/j.semarthrit.2024.152517","article-title":"Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients","volume":"68","author":"L\u00f3pez-Maraver","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2026080405101039000_12.3.e006860.88","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/jcm9010277","article-title":"Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: a multicenter retrospective study","volume":"9","author":"Cassone","year":"2020","journal-title":"JCM"},{"key":"2026080405101039000_12.3.e006860.89","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/jcm12030957","article-title":"Evolution of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a retrospective exploratory study","volume":"12","author":"Venerito","year":"2023","journal-title":"JCM"},{"key":"2026080405101039000_12.3.e006860.90","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003789","article-title":"Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT register","volume":"10","author":"Rudi","year":"2024","journal-title":"RMD Open"},{"key":"2026080405101039000_12.3.e006860.91","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/OARRR.S462662","article-title":"Safety of tocilizumab on rheumatoid arthritis in patients with interstitial lung disease","volume":"16","author":"Otsuji","year":"2024","journal-title":"Open Access Rheumatol"},{"key":"2026080405101039000_12.3.e006860.92","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00296-021-04934-z","article-title":"Bronchiectasis is as crucial as interstitial lung disease in the severe pneumonia that occurs during treatment with biologic DMARDs in rheumatoid arthritis: a retrospective cohort study in a single facility","volume":"42","author":"Honne","year":"2022","journal-title":"Rheumatol Int"},{"key":"2026080405101039000_12.3.e006860.93","first-page":"2071","article-title":"Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data","volume":"40","author":"Kalyoncu","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2026080405101039000_12.3.e006860.94","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa577"},{"key":"2026080405101039000_12.3.e006860.95","first-page":"1781","article-title":"Uncovering risk factors for adverse events and infections in rheumatoid arthritis and rheumatoid arthritis with interstitial lung disease under treatment with biologics or targeted synthetic DMARDs: insights from the KOBIO Registry","volume":"42","author":"Kim","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"2026080405101039000_12.3.e006860.96","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221135314","article-title":"Protective effect of methotrexate on lung function and mortality in rheumatoid arthritis-related interstitial lung disease: a retrospective cohort study","volume":"16","author":"Kim","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"2026080405101039000_12.3.e006860.97","first-page":"247","article-title":"Retention rate and safety of biologic and targeted synthetic DMARDs in patients with RA-associated interstitial lung disease: a KOBIO Registry study","volume":"37","author":"Lee","year":"2023","journal-title":"BioDrugs"},{"key":"2026080405101039000_12.3.e006860.98","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10071480","article-title":"Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis-associated interstitial lung disease","volume":"10","author":"Mena-V\u00e1zquez","year":"2022","journal-title":"Biomedicines"},{"key":"2026080405101039000_12.3.e006860.99","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S2665-9913(24)00265-0","article-title":"Advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease: a retrospective, active-comparator, new-user, cohort study","volume":"7","author":"England","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"2026080405101039000_12.3.e006860.100","doi-asserted-by":"crossref","first-page":"152735","DOI":"10.1016\/j.semarthrit.2025.152735","article-title":"Non-TNFi biologic and targeted synthetic DMARDs in rheumatoid arthritis-associated interstitial lung disease: a propensity score-matched, active-comparator, new-user study","volume":"73","author":"Frideres","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"2026080405101039000_12.3.e006860.101","doi-asserted-by":"crossref","first-page":"152636","DOI":"10.1016\/j.semarthrit.2025.152636","article-title":"Mortality and medical utilization in rheumatoid arthritis associated interstitial lung disease: a real-world, large-scale retrospective study comparing Janus kinase inhibitors and tumor necrosis factor inhibitors","volume":"71","author":"Shih","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"2026080405101039000_12.3.e006860.102","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1093\/rheumatology\/keaf314","article-title":"Baricitinib in rheumatoid arthritis-interstitial lung disease: a literature review and national multicentre study of 72 patients","volume":"64","author":"Serrano-Combarro","year":"2025","journal-title":"Rheumatology"},{"key":"2026080405101039000_12.3.e006860.103","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005062","article-title":"Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study","volume":"11","author":"Triboulet","year":"2025","journal-title":"RMD Open"},{"key":"2026080405101039000_12.3.e006860.104","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13075-022-02842-6","article-title":"Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013\u20132018","volume":"24","author":"Jung","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2026080405101039000_12.3.e006860.105","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/rheumatology\/keaa702","article-title":"Tuberculosis risk with biologics by screening-guided preventive strategy in rheumatoid arthritis under intermediate tuberculosis burden","volume":"60","author":"Shin","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026080405101039000_12.3.e006860.106","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/mr\/roac011","article-title":"Abatacept ameliorates both glandular and extraglandular involvements in patients with Sj\u00f6gren\u2019s syndrome associated with rheumatoid arthritis: findings from an open-label, multicentre, 1-year, prospective study: the ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sj\u00f6gren\u2019s Syndrome Endocrinopathy) and ROSE II trials","volume":"33","author":"Tsuboi","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026080405101039000_12.3.e006860.107","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes190"},{"key":"2026080405101039000_12.3.e006860.108","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/rheumatology\/keac448","article-title":"The effect of group-based cognitive behavioural therapy for insomnia in patients with rheumatoid arthritis: a randomized controlled trial","volume":"62","author":"Latocha","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2026080405101039000_12.3.e006860.109","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40744-023-00612-7","article-title":"Tofacitinib efficacy in patients with rheumatoid arthritis and probable depression\/anxiety: post hoc analysis of phase 3 and 3b\/4 randomized controlled trials","volume":"11","author":"Citera","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026080405101039000_12.3.e006860.110","doi-asserted-by":"crossref","unstructured":"Jeong S , Choi S , Park SM , et al . Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study. Arthritis Res Ther 2022;24. doi:10.1186\/s13075-022-02871-1","DOI":"10.1186\/s13075-022-02871-1"},{"key":"2026080405101039000_12.3.e006860.111","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"2026080405101039000_12.3.e006860.112","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/mr\/roaf017","article-title":"Three-year safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Final analysis of an all-case postmarketing surveillance study","volume":"35","author":"Kuwana","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026080405101039000_12.3.e006860.113","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.23098","article-title":"Response to biologic drugs in patients with rheumatoid arthritis and antidrug antibodies","volume":"6","author":"Bitoun","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026080405101039000_12.3.e006860.114","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223916"},{"key":"2026080405101039000_12.3.e006860.115","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"2026080405101039000_12.3.e006860.116","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X251321917","article-title":"Major adverse cardiovascular events or venous thromboembolism in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a nationwide, population-based cohort study","volume":"17","author":"Kao","year":"2025","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026080405101039000_12.3.e006860.117","doi-asserted-by":"crossref","first-page":"152721","DOI":"10.1016\/j.semarthrit.2025.152721","article-title":"Risk of major adverse cardiovascular events following targeted therapy in patients with rheumatoid arthritis: a real-world analysis stratified by cardiovascular risk","volume":"73","author":"You","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"2026080405101039000_12.3.e006860.118","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/art.43188","article-title":"Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with JAK inhibitors compared with biologic disease-modifying antirheumatic drugs: data from an international collaboration of registries","volume":"77","author":"Aymon","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"2026080405101039000_12.3.e006860.119","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223715"},{"key":"2026080405101039000_12.3.e006860.120","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221276"},{"key":"2026080405101039000_12.3.e006860.121","doi-asserted-by":"crossref","DOI":"10.3390\/medicina60121982","article-title":"Effectiveness and Predictors of Long-Term Treatment Response to Tofacitinib in Rheumatoid Arthritis Cohort: General Analysis and Focus on High-Cardiovascular-Risk Subgroup-A Multicenter Study","volume":"60","author":"Priora","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"2026080405101039000_12.3.e006860.122","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005371","article-title":"Benefit\u2013risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease","volume":"11","author":"Burmester","year":"2025","journal-title":"RMD Open"},{"key":"2026080405101039000_12.3.e006860.123","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005033","article-title":"Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes","volume":"11","author":"Mariette","year":"2025","journal-title":"RMD Open"},{"key":"2026080405101039000_12.3.e006860.124","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s40744-024-00719-5","article-title":"Tofacitinib safety and effectiveness in Canadian patients with rheumatoid arthritis by cardiovascular risk enrichment: subanalysis of the CANTORAL study","volume":"11","author":"Haraoui","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026080405101039000_12.3.e006860.125","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s40744-024-00693-y","article-title":"Geographical differences in the safety and efficacy of tofacitinib versus TNFi: a post hoc analysis of ORAL Surveillance","volume":"11","author":"Batko","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026080405101039000_12.3.e006860.126","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222259"},{"key":"2026080405101039000_12.3.e006860.127","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221915"},{"key":"2026080405101039000_12.3.e006860.128","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092932"},{"key":"2026080405101039000_12.3.e006860.129","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"2026080405101039000_12.3.e006860.130","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex489"},{"key":"2026080405101039000_12.3.e006860.131","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/art.39801","article-title":"A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy","volume":"68","author":"Kremer","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026080405101039000_12.3.e006860.132","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9055"},{"key":"2026080405101039000_12.3.e006860.133","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor \u03b1 inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"The Lancet"},{"key":"2026080405101039000_12.3.e006860.134","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31116-4"},{"key":"2026080405101039000_12.3.e006860.135","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507247"},{"key":"2026080405101039000_12.3.e006860.136","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard-2023-224482","article-title":"Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)","volume":"82","author":"Fleischmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026080405101039000_12.3.e006860.137","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1136\/ard-2023-224449","article-title":"Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)","volume":"82","author":"Taylor","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026080405101039000_12.3.e006860.138","doi-asserted-by":"crossref","unstructured":"Tesser J , G\u00fcl A , Olech E , et al . Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II\/III trials. Arthritis Res Ther 2023;25. doi:10.1186\/s13075-023-03154-z","DOI":"10.1186\/s13075-023-03154-z"},{"key":"2026080405101039000_12.3.e006860.139","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008250"},{"key":"2026080405101039000_12.3.e006860.140","doi-asserted-by":"crossref","unstructured":"Choy E , Groves L , Sugrue D , et al . Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study. BMC Rheumatol 2021;5. doi:10.1186\/s41927-020-00173-0","DOI":"10.1186\/s41927-020-00173-0"},{"key":"2026080405101039000_12.3.e006860.141","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13075-022-02744-7","article-title":"Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry","volume":"24","author":"Ochi","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2026080405101039000_12.3.e006860.142","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1093\/rheumatology\/keae265","article-title":"Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study","volume":"63","author":"Watanabe","year":"2024","journal-title":"Rheumatology"},{"key":"2026080405101039000_12.3.e006860.143","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/mr\/roae077","article-title":"Efficacy and safety of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis","volume":"35","author":"Anno","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026080405101039000_12.3.e006860.144","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1093\/rheumatology\/keae334","article-title":"Comparison of anti-IL-6 receptor and JAK inhibitors in patients with rheumatoid arthritis from the real-world practice FIRST registry","volume":"64","author":"Miyazaki","year":"2025","journal-title":"Rheumatology"},{"key":"2026080405101039000_12.3.e006860.145","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/rheumatology\/kead515","article-title":"Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?","volume":"63","author":"Lauper","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026080405101039000_12.3.e006860.146","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.ard.2025.05.014","article-title":"Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register","volume":"84","author":"Schaefer","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026080405101039000_12.3.e006860.147","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004987","article-title":"Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry","volume":"11","author":"Miyazaki","year":"2025","journal-title":"RMD Open"},{"key":"2026080405101039000_12.3.e006860.148","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222835"},{"key":"2026080405101039000_12.3.e006860.149","doi-asserted-by":"crossref","first-page":"169","DOI":"10.46497\/ArchRheumatol.2022.8965","article-title":"Measuring the impact of an educational intervention in rheumatoid arthritis: an open-label, randomized trial","volume":"37","author":"Genevi\u00e8ve","year":"2022","journal-title":"Archives of Rheumatology"},{"key":"2026080405101039000_12.3.e006860.150","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1089\/g4h.2019.0167","article-title":"Exergaming as an additional tool in rehabilitation of young patients with rheumatoid arthritis: a pilot randomized controlled trial","volume":"9","author":"Ambrosino","year":"2020","journal-title":"Games Health J"},{"key":"2026080405101039000_12.3.e006860.151","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/mr\/roae097","article-title":"Impact of orthopaedic surgical intervention on difficult-to-treat rheumatoid arthritis: a propensity score-matched study","volume":"35","author":"Toyama","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026080405101039000_12.3.e006860.152","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa860"},{"key":"2026080405101039000_12.3.e006860.153","first-page":"388","article-title":"2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer","volume":"84","author":"Sebbag","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026080405101039000_12.3.e006860.154","doi-asserted-by":"crossref","DOI":"10.1186\/s42234-023-00138-x","article-title":"Clinical safety and feasibility of a novel implantable neuroimmune modulation device for the treatment of rheumatoid arthritis: initial results from the randomized, double-blind, sham-controlled RESET-RA study","volume":"10","author":"Peterson","year":"2024","journal-title":"Bioelectron Med"},{"key":"2026080405101039000_12.3.e006860.155","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40744-025-00798-y","article-title":"Neuroimmune modulation for drug-refractory rheumatoid arthritis: long-term safety and efficacy in patients enrolled in a pilot vagus nerve stimulation study","volume":"12","author":"Gaylis","year":"2025","journal-title":"Rheumatol Ther"},{"key":"2026080405101039000_12.3.e006860.156","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-024-05569-x","article-title":"Efficacy and safety of current therapies for difficult-to-treat rheumatoid arthritis: a systematic review and network meta-analysis","volume":"22","author":"Su","year":"2024","journal-title":"J Transl Med"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2026-006860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:10:46Z","timestamp":1785845446000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2026-006860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":156,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,8,4]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/rmdopen-2026-006860"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2026-006860","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}